186 related articles for article (PubMed ID: 28401570)
1. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[
Bauer M; Wulkersdorfer B; Karch R; Philippe C; Jäger W; Stanek J; Wadsak W; Hacker M; Zeitlinger M; Langer O
Br J Clin Pharmacol; 2017 Sep; 83(9):1991-1999. PubMed ID: 28401570
[TBL] [Abstract][Full Text] [Related]
2. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
3. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study.
Bauer M; Karch R; Zeitlinger M; Philippe C; Römermann K; Stanek J; Maier-Salamon A; Wadsak W; Jäger W; Hacker M; Müller M; Langer O
J Cereb Blood Flow Metab; 2015 May; 35(5):743-6. PubMed ID: 25669913
[TBL] [Abstract][Full Text] [Related]
4. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [
Tournier N; Goutal S; Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Caillé F; Breuil L; Stanek J; Freeman AF; Novarino G; Truillet C; Wanek T; Langer O
J Cereb Blood Flow Metab; 2021 Jul; 41(7):1634-1646. PubMed ID: 33081568
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
6. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
[TBL] [Abstract][Full Text] [Related]
7. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Modeling of (
García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
[TBL] [Abstract][Full Text] [Related]
9. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier.
Bauer M; Römermann K; Karch R; Wulkersdorfer B; Stanek J; Philippe C; Maier-Salamon A; Haslacher H; Jungbauer C; Wadsak W; Jäger W; Löscher W; Hacker M; Zeitlinger M; Langer O
Clin Pharmacol Ther; 2016 Aug; 100(2):131-41. PubMed ID: 26940368
[TBL] [Abstract][Full Text] [Related]
10. Assessment of P-Glycoprotein Transport Activity at the Human Blood-Retina Barrier with (
Bauer M; Karch R; Tournier N; Cisternino S; Wadsak W; Hacker M; Marhofer P; Zeitlinger M; Langer O
J Nucl Med; 2017 Apr; 58(4):678-681. PubMed ID: 27738009
[TBL] [Abstract][Full Text] [Related]
11. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.
Bauer M; Zeitlinger M; Karch R; Matzneller P; Stanek J; Jäger W; Böhmdorfer M; Wadsak W; Mitterhauser M; Bankstahl JP; Löscher W; Koepp M; Kuntner C; Müller M; Langer O
Clin Pharmacol Ther; 2012 Feb; 91(2):227-33. PubMed ID: 22166851
[TBL] [Abstract][Full Text] [Related]
12. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.
Toornvliet R; van Berckel BN; Luurtsema G; Lubberink M; Geldof AA; Bosch TM; Oerlemans R; Lammertsma AA; Franssen EJ
Clin Pharmacol Ther; 2006 Jun; 79(6):540-8. PubMed ID: 16765142
[TBL] [Abstract][Full Text] [Related]
13. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
14. P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of
Auvity S; Caillé F; Marie S; Wimberley C; Bauer M; Langer O; Buvat I; Goutal S; Tournier N
J Nucl Med; 2018 Oct; 59(10):1609-1615. PubMed ID: 29748235
[TBL] [Abstract][Full Text] [Related]
15. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
[TBL] [Abstract][Full Text] [Related]
16. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
17. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
Wanek T; Zoufal V; Brackhan M; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Pahnke J; Langer O
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153231
[TBL] [Abstract][Full Text] [Related]
18. Quantification of P-glycoprotein function at the human blood-brain barrier using [
Mossel P; Arif WM; De Souza GS; Varela LG; van der Weijden CWJ; Boersma HH; Willemsen ATM; Boellaard R; Elsinga PH; Borra RJH; Dierckx RAJO; Lammertsma AA; Bartels AL; Luurtsema G
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3917-3927. PubMed ID: 37552369
[TBL] [Abstract][Full Text] [Related]
19. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
[TBL] [Abstract][Full Text] [Related]
20. Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate
Tournier N; Bauer M; Pichler V; Nics L; Klebermass EM; Bamminger K; Matzneller P; Weber M; Karch R; Caillé F; Auvity S; Marie S; Jäger W; Wadsak W; Hacker M; Zeitlinger M; Langer O
J Nucl Med; 2019 Jul; 60(7):985-991. PubMed ID: 30630940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
